Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDTX Cidara Therapeutics	$49.45 +3.0%	$25.04	$10.14 ▼ $56.83	$620.45M	0.79	167,397 shs	3.75 million shs
HUMA Humacyte	$2.12 -4.5%	$2.06	$1.15 ▼ $9.79	$328.85M	2	3.82 million shs	7.26 million shs
PROK ProKidney	$0.67 -7.5%	$0.80	$0.46 ▼ $2.59	$195.73M	1.35	692,490 shs	12.36 million shs
TCRR TCR2 Therapeutics	$1.48	$1.65	$0.82 ▼ $3.88	$58.11M	1.95	494,777 shs	N/A

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDTX Cidara Therapeutics	0.00%	+135.25%	+124.57%	+120.86%	+341.52%
HUMA Humacyte	0.00%	-8.23%	-23.47%	+8.16%	-57.60%
PROK ProKidney	0.00%	+1.30%	-7.19%	-26.52%	-70.54%
TCRR TCR2 Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CDTX Cidara Therapeutics	3.7972 of 5 stars	3.6	2.0	0.0	4.6	3.1	0.0	0.0
HUMA Humacyte	2.6561 of 5 stars	3.5	3.0	0.0	0.0	1.4	2.5	0.6
PROK ProKidney	2.5258 of 5 stars	3.2	0.0	0.0	0.0	3.3	4.2	0.6
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDTX Cidara Therapeutics	3.11	Buy	$55.43	12.09% Upside
HUMA Humacyte	3.00	Buy	$11.71	452.56% Upside
PROK ProKidney	2.33	Hold	$4.50	572.95% Upside
TCRR TCR2 Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TCRR, CDTX, HUMA, and PROK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/24/2025	CDTX Cidara Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$35.00 ➝ $75.00
6/24/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$50.00 ➝ $68.00
6/23/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$41.00 ➝ $53.00
6/23/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$36.00 ➝ $54.00
6/23/2025	CDTX Cidara Therapeutics	WBB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$45.00
6/18/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$41.00
6/10/2025	CDTX Cidara Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/4/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $36.00
6/2/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$47.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDTX Cidara Therapeutics	$1.27M	488.66	N/A	N/A	$14.92 per share	3.31
HUMA Humacyte	$1.57M	209.46	N/A	N/A	($0.41) per share	-5.17
PROK ProKidney	$80K	2,446.61	N/A	N/A	($3.41) per share	-0.20
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A	$2.58 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDTX Cidara Therapeutics	-$169.83M	-$29.47	N/A	N/A	N/A	N/A	-73.04%	-54.28%	8/12/2025 (Estimated)
HUMA Humacyte	-$148.70M	-$0.69	N/A	N/A	N/A	N/A	N/A	-73.59%	8/12/2025 (Estimated)
PROK ProKidney	-$61.19M	-$0.60	N/A	N/A	N/A	N/A	N/A	-15.03%	8/8/2025 (Estimated)
TCRR TCR2 Therapeutics	-$151.82M	-$4.20	N/A	N/A	N/A	N/A	-97.81%	-69.35%	N/A

Latest TCRR, CDTX, HUMA, and PROK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	HUMA Humacyte	-$0.19	-$0.10	+$0.09	$0.28	$0.46 million	$0.52 million
5/12/2025	Q1 2025	PROK ProKidney	-$0.16	-$0.13	+$0.03	-$0.13	N/A	$0.23 million
5/8/2025	Q1 2025	CDTX Cidara Therapeutics	-$5.45	-$1.66	+$3.79	-$1.66	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A
TCRR TCR2 Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDTX Cidara Therapeutics	N/A	3.87	3.87
HUMA Humacyte	0.36	3.68	3.28
PROK ProKidney	N/A	10.96	10.96
TCRR TCR2 Therapeutics	N/A	2.96	2.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CDTX Cidara Therapeutics	35.82%
HUMA Humacyte	44.71%
PROK ProKidney	51.59%
TCRR TCR2 Therapeutics	64.76%

Insider Ownership

Company	Insider Ownership
CDTX Cidara Therapeutics	3.89%
HUMA Humacyte	5.10%
PROK ProKidney	41.49%
TCRR TCR2 Therapeutics	25.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CDTX Cidara Therapeutics	90	12.55 million	12.06 million	No Data
HUMA Humacyte	150	155.12 million	147.21 million	Optionable
PROK ProKidney	3	292.70 million	171.26 million	Optionable
TCRR TCR2 Therapeutics	137	39.26 million	29.44 million	Not Optionable

TCRR, CDTX, HUMA, and PROK Headlines

Recent News About These Companies

TCR2 Therapeutics gets grant for recombinant nucleic acid encoding TCR fusion protein for cancer treatment

April 17, 2024 | pharmaceutical-technology.comP

Poseida Therapeutics Inc Ordinary Shares PSTX

February 25, 2024 | morningstar.comM

DICE Therapeutics Inc.

June 20, 2023 | wsj.com

Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company

June 1, 2023 | finance.yahoo.com

TCR2 Therapeutics Insider Trades Send a Signal

May 16, 2023 | benzinga.com

Recap: TCR2 Therapeutics Q1 Earnings

May 12, 2023 | msn.com

10-Q: TCR2 THERAPEUTICS INC.

May 11, 2023 | marketwatch.com

TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 11, 2023 | finance.yahoo.com

Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Could Be Quite Risky

April 15, 2023 | finance.yahoo.com

Mizuho Downgrades Tcr2 Therapeutics (TCRR)

March 25, 2023 | msn.com

TCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at Mizuho Securities

March 23, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY)

March 23, 2023 | markets.businessinsider.com

TCR2 Therapeutics: TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

March 23, 2023 | finanznachrichten.de

TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

March 23, 2023 | finance.yahoo.com

What To Know About Jefferies's Downgrade of TCR2 Therapeutics

March 9, 2023 | msn.com

4 Analysts Have This to Say About TCR2 Therapeutics

March 9, 2023 | markets.businessinsider.com

TCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at H.C. Wainwright

March 8, 2023 | markets.businessinsider.com

Shareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with Adaptimmune

March 6, 2023 | benzinga.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TCR² Therapeutics Inc. Buyout

March 6, 2023 | benzinga.com

Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?

March 6, 2023 | investorplace.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRR, CDTX, HUMA, and PROK Company Descriptions

Cidara Therapeutics NASDAQ:CDTX

$49.45 +1.42 (+2.96%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$48.14 -1.32 (-2.66%)

As of 06/27/2025 07:39 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Humacyte NASDAQ:HUMA

$2.12 -0.10 (-4.50%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.14 +0.02 (+0.94%)

As of 06/27/2025 07:57 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

ProKidney NASDAQ:PROK

$0.67 -0.05 (-7.50%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.70 +0.03 (+5.13%)

As of 06/27/2025 07:38 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

TCR2 Therapeutics NASDAQ:TCRR

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time